Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07628257
Starting soon Not applicable

Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up

NCT07628257 · tracked via the Priya Life Science France tracker
Sponsor
Centre Paul Strauss
Phase
Not applicable
Started
2026-09-15
Last updated
2026-06-04

Condition(s) studied

Glioblastoma

Investigational drug(s) / intervention(s)

18F-FDG PET/MRI with additional DTI and rs-fMRI sequences

18F-FDG PET/MRI with additional DTI and rs-fMRI sequences: fluorodeoxyglucose (Fluor18) (18F-FDG) PET/MRI with additional DTI and rs-fMRI sequences correlation with neuropsychological tests

Study summary

The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms.

This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients * Patients with glioblastoma * Patients treated in the Nuclear Medicine \& Molecular Imaging Department of the Strauss Institute for PET/MRI scans for: * Preoperative metabolic evaluation of a brain-expanding lesion Exclusion Criteria: * Contraindications to MRI * Minor or incapacitated adult * Patient deprived of liberty * Patient under legal guardianship * Patient unable to consent * Pregnant or breastfeeding woman

Primary outcome measure(s)

  • Correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance before surgery — Before surgery

Trial sites (1)

FacilityCityRegionStatus
Institut public de cancérologie Strauss Europe Strasbourg France

More Centre Paul Strauss trials in France

Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study Recruiting
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma Recruiting
Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy Recruiting
Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI Recruiting
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer Active, not recruiting

Other trials for the same condition

A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression Recruiting
Treatment Intensification With Temozolomide in Adults With a Glioblastoma Active, not recruiting
MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy) Recruiting
Predictive Value of Soluble CD146 in Glioblastoma Patients Recruiting
Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors. Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07628257 on ClinicalTrials.gov ↗ ← All trials in France